VANCOUVER, BC, June 11, 2020 /CNW/ - Numinus Wellness Inc. (TSX-V: NUMI) ("Numinus" or the "Company") wishes to correct the original news release dated June 11, 2020 that contained the following errors:
Below is the corrected news release in its entirety with the updated information.
Numinus receives Health Canada licence amendment to produce and extract psilocybin from mushrooms
Numinus becomes first publicly traded company in Canada approved to conduct research of this kind under a Health Canada licence
VANCOUVER (June 11, 2020)Numinus Wellness Inc. (TSX-V: NUMI) ("Numinus" or the "Company") has received Health Canada approval to amend the Company's existing Licence under the Controlled Drug and Substances Act to allow Numinus researchers to conduct research to standardize the extraction of psilocybin from mushrooms. The amendment means Numinus is the first publicly traded company in Canada to be granted a licence by Health Canada to conduct research of this kind.
With this regulatory approval, Numinus is able to proceed with the production of naturally sourced, sustainable psilocybin for research purposes that will support the emerging field of psychedelic assisted therapy and research, at lower costs to currently produced synthetic psilocybin. The licence also allows Numinus to develop and licence its own exclusive IP for further product development in partnership with leading research organizations something the research community has been seeking to secure. The work will be eligible for the Government of Canada's Scientific Research and Experimental Development (SR&ED) tax incentive program and will lay a foundation for grant applications.
"We are proud to be at the forefront of a new therapeutic category by advancing evidence-based science focused on wellness and personal connection at its core," says Numinus CEO Payton Nyquvest. "Numinus is the only publicly traded company in Canada approved to develop a consistent psilocybin extraction method from naturally-produced mushrooms at a time when alternative therapeutic methods are increasingly being investigated and demand from clinical research is growing."
Working from the 7,000 square-foot Numinus Bioscience research facility and laboratory, senior research scientists Dr. Kristina Grotzinger and Dr. Bernd Keller will focus on developing a proprietary extraction method from mushrooms to allow for consistent dosing and application of naturally produced psilocybin. Once a proprietary method has been developed, the Company intends to explore supply agreements with leading research organizations to make use of the product in their clinical and therapeutic work.
Researchers at Johns Hopkins University, the Multidisciplinary Association for Psychedelic Studies (MAPS) and other leading researchers have published studies showing the benefits of psychedelic substances in treating a range of mental health issues. Further, the US Food and Drug Administration has granted breakthrough therapy status for psilocybin for the treatment of depression illustrating the growing demand for therapeutic access to psilocybin.
"In most cases, the creation of synthetic compounds are less pure than those found in nature, which is the case with psilocybin," says Dr. Grotzinger. "There is risk of contamination from solvents, gases and other chemicals, which makes them less safe to work with and requires added safety and processing expense. By working directly with the mushroom in its natural state, these risks are reduced, as is the cost to extract the psilocybin." Grotzinger added that standardized plant or fungi extracts are accepted by European standards and are a common dosage form in Europe.
About NuminusNuminus is a Vancouver-based health care company helping to support the universal desire to heal and be well. Through its wholly-owned subsidiary Salvation Botanicals, Numinus has a Health Canada cannabis testing licence that allows the Company to test and analyze cannabis products from licensed producers. In addition, it is a late-stage applicant to receive a Health Canada standard processing licence to produce cannabis products. Numinus, through the same subsidiary, also has a dealer's licence which allows the Company to test, possess, buy and sell MDMA, psilocybin, psilocin, DMT and mescaline. The Health Canada license also allows import/export, testing and R&D of these substances. The expanded licence will allow Numinus to support the growing number of studies on the potential benefits of psychedelic therapies through research projects, product development, and the supply and distribution of these substances. Numinus Wellness is dedicated to therapies that enhance and supplement existing options for people wanting lasting physical, mental and emotional health with psychedelic treatments at its core when approved for therapeutic and research use. Psychedelics will be part of this offering but will only be available for treatment once approved by regulators and governing bodies a process Numinus is helping to support. For more information, visit http://www.numinus.ca.
Forward Looking StatementsThis news release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are "forward-looking statements." Forward-looking statements can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward looking statements. Such risks and uncertainties include, among others, dependence on obtaining and maintaining regulatory approvals, including acquiring and renewing federal, provincial, municipal, local or other licenses and any inability to obtain all necessary governmental approvals licenses and permits to operate and expand the Company's facilities; regulatory or political change such as changes in applicable laws and regulations, including federal and provincial legalization, due to inconsistent public opinion, perception of the medical-use and adult-use marijuana industry, bureaucratic delays or inefficiencies or any other reasons; any other factors or developments which may hinder market growth; the Company's limited operating history and lack of historical profits; reliance on management; the Company's requirements for additional financing, and the effect of capital market conditions and other factors on capital availability; competition, including from more established or better financed competitors; and the need to secure and maintain corporate alliances and partnerships, including with research and development institutions, customers and suppliers. These factors should be considered carefully, and readers are cautioned not to place undue reliance on such forward-looking statements. Although the Company has attempted to identify important risk factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other risk factors that cause actions, events or results to differ from those anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements. The Company has no obligation to update any forward-looking statement, even if new information becomes available as a result of future events, new information or for any other reason except as required by law.
SOURCE Numinus Wellness Inc.
For further information: Investor Inquiries: [emailprotected]; Media Inquiries: Emily Edwards, NATIONAL, [emailprotected], 604-842-6490; General Inquiries: [emailprotected], 1-833-NUM-INUS (1-833-686-4687); Pour investir et obtenir des renseignements gnraux en franais: Remy Scalabrini, Maricom, [emailprotected], 888-585-6274
More here:
- 8 Mystical Herbs and Legal Psychedelics For Lucid Dreaming - December 8th, 2016 [December 8th, 2016]
- Psychedelics: LSD, Mushrooms, Salvia | Facts | Drug Policy ... - December 10th, 2016 [December 10th, 2016]
- FS Book Company - Marijuana Books - December 12th, 2016 [December 12th, 2016]
- Psychedelic - PsychonautWiki - December 27th, 2016 [December 27th, 2016]
- From Alzheimer's To Psychedelics, 2016 Was A Good Year For ... - January 3rd, 2017 [January 3rd, 2017]
- LSD - Psychedelic Effects - The Good Drugs Guide - January 5th, 2017 [January 5th, 2017]
- THC - Psychedelics - January 29th, 2017 [January 29th, 2017]
- Psychedelics | Pharmacological Reviews - January 30th, 2017 [January 30th, 2017]
- Dorian Yates reveals all on steroids, body dysmorphia, psychedelics, cannabis and yoga - Express.co.uk - February 7th, 2017 [February 7th, 2017]
- Psychedelic drug therapy including magic mushrooms, LSD and ... - CBS News - February 7th, 2017 [February 7th, 2017]
- Psychedelics Being Tested For Use In Treating Various Conditions - CBS Local - February 8th, 2017 [February 8th, 2017]
- The psychedelic renaissance - Boulder Weekly - February 9th, 2017 [February 9th, 2017]
- Buy psychedelics online : Chinglabs.com - February 12th, 2017 [February 12th, 2017]
- Psychedelic drugs like magic mushrooms and LSD have key ... - Yahoo Finance - February 13th, 2017 [February 13th, 2017]
- Psychedelics a Viable Therapeutic Option for Depression - Psychiatry Advisor - February 14th, 2017 [February 14th, 2017]
- Is Silicon Valley Onto Something With Its LSD Microdosing? - Newsweek - February 15th, 2017 [February 15th, 2017]
- News Releases - Noozhawk - February 16th, 2017 [February 16th, 2017]
- A Revolution in the Science of Psychedelics is Happening in Boulder - 303 Magazine - February 16th, 2017 [February 16th, 2017]
- When Reality Is More Intense Than Psychedelics: Strand Of Oaks ... - NPR - February 17th, 2017 [February 17th, 2017]
- Psychedelics Help Reduce Opioid Addiction, According to New Study - AlterNet - February 22nd, 2017 [February 22nd, 2017]
- Psychedelics May Help Reduce Opioid Addiction, According To ... - Huffington Post - February 23rd, 2017 [February 23rd, 2017]
- Psychedelics Help Reduce Opioid Addiction, According to New Study - eNews Park Forest - February 24th, 2017 [February 24th, 2017]
- Psychedelics Could Play A Role In Tackling The Opioid Epidemic - Huffington Post - February 24th, 2017 [February 24th, 2017]
- Meet The People's Champion of Psychedelic Drugs - Narratively - February 27th, 2017 [February 27th, 2017]
- How psychedelics like psilocybin and LSD actually change the way ... - Yahoo Finance - February 27th, 2017 [February 27th, 2017]
- First U. student group on studying psychedelics holds open house - The Daily Princetonian - February 27th, 2017 [February 27th, 2017]
- How psychedelics like psilocybin and LSD actually change the way people see the world - Businessinsider India - February 28th, 2017 [February 28th, 2017]
- Psychedelics Help Reduce Opioid Addiction, According to New ... - February 28th, 2017 [February 28th, 2017]
- WATCH: A Public Policy Expert Explains How to Safely Deregulate LSD and Other Psychedelics - AlterNet - March 7th, 2017 [March 7th, 2017]
- Quotes About Psychedelics (48 quotes) - March 7th, 2017 [March 7th, 2017]
- Inside the Psychedelic Underground - RollingStone.com - March 9th, 2017 [March 9th, 2017]
- What Psychedelics Really Do to Your Brain - Rolling Stone - RollingStone.com - March 10th, 2017 [March 10th, 2017]
- Hallucinogens Help, According to a Mom's Memoir and Son's Documentary - Bedford + Bowery - April 8th, 2017 [April 8th, 2017]
- Meditation and the psychedelic drug ayahuasca seem to change the brain in surprisingly similar ways - Businessinsider India - April 8th, 2017 [April 8th, 2017]
- Tripping out: the highs and lows of psychedelic therapy - Marie Claire UK - April 8th, 2017 [April 8th, 2017]
- Stop Policing Psychedelic Science - Motherboard - June 6th, 2017 [June 6th, 2017]
- America's Trippiest Chemist: Making Psychedelics 'Was Fun' - Motherboard - June 6th, 2017 [June 6th, 2017]
- The Three Types of Hallucinogens: Psychedelics ... - June 7th, 2017 [June 7th, 2017]
- Cary Grant was one of the first to benefit from LSD therapy - Quartz - June 11th, 2017 [June 11th, 2017]
- What it's like to take psychedelics in small doses at breakfast - New Scientist - June 14th, 2017 [June 14th, 2017]
- 'Changing Our Minds' explores psychedelic drugs and spiritual healing - Religion News Service - June 14th, 2017 [June 14th, 2017]
- Q&A With Psychedelic Stand-Up and LaughFest Headliner Shane Mauss - Flagpole Magazine - June 20th, 2017 [June 20th, 2017]
- Q&A: LaughFest comedian talks science and psychedelics - Red and Black - June 20th, 2017 [June 20th, 2017]
- 'Changing Our Minds' explores psychedelic drugs and spiritual healing - The Daily Tribune - June 21st, 2017 [June 21st, 2017]
- Shane Mauss brings Good Trip Comedy Tour to town - Chattanooga Times Free Press - June 22nd, 2017 [June 22nd, 2017]
- 'Changing Our Minds' explores psychedelic drugs and spiritual healing - The Oakland Press - June 22nd, 2017 [June 22nd, 2017]
- Director Ana Lily Amirpour on Cannibalism, Psychedelics, and 'Horrifying' Racism Allegations - Jezebel - June 23rd, 2017 [June 23rd, 2017]
- Majority of Americans ready to embrace psychedelic therapy - YouGov US - June 24th, 2017 [June 24th, 2017]
- The Refugee Funding America's Psychedelic Renaissance - VICE - June 24th, 2017 [June 24th, 2017]
- Open Your Mind This Weekend at Europe's Largest Psychedelic Conference - VolteFace Magazine (blog) - June 27th, 2017 [June 27th, 2017]
- Psychedelics and Virtual Reality Make a Trendy but Illegal Therapy - Inverse - June 27th, 2017 [June 27th, 2017]
- The war on drugs is back. Will psychedelic drug research survive? - The Verge - June 29th, 2017 [June 29th, 2017]
- Tune in, Turn on, Stay in School - Study Breaks - July 2nd, 2017 [July 2nd, 2017]
- Cannabist Show: He's psychedelic comedian Shane Mauss - The Cannabist - July 2nd, 2017 [July 2nd, 2017]
- The brain on DMT: mapping the psychedelic drug's effects - Wired.co.uk - July 3rd, 2017 [July 3rd, 2017]
- Psychedelics Could Help Asia's Mental Health Care, But Stigma Remains Roadblock - TheFix.com - July 3rd, 2017 [July 3rd, 2017]
- Is LSD the new coffee? - FactorDaily - July 4th, 2017 [July 4th, 2017]
- My grandfather was a death row doctor. He tested psychedelic drugs on Texas inmates. - Texas Tribune - July 5th, 2017 [July 5th, 2017]
- About Us | Trusted News Source for Psychedelic Research ... - July 6th, 2017 [July 6th, 2017]
- Do Psychedelic Drugs Cause the 'Prophetic Effect'? - Breaking Israel News - July 11th, 2017 [July 11th, 2017]
- Are psychedelics the new medical marijuana? - WTSP 10 News - July 14th, 2017 [July 14th, 2017]
- Psychiatrists Say Cannabis Medicine Has Psychedelic Properties - The Marijuana Times - July 15th, 2017 [July 15th, 2017]
- Can Psychedelics Be Therapy? Allow Research to Find Out - New York Times - July 17th, 2017 [July 17th, 2017]
- Countdown To (Legalized) Ecstasy! Rick Doblin, MAPS, & the Psychedelic Renaissance [Podcast] - Reason (blog) - July 20th, 2017 [July 20th, 2017]
- Should We Reclassify Marijuana as a Hallucinogen? - Big Think - July 20th, 2017 [July 20th, 2017]
- Do You Take Drugs at Festivals? This Initiative is Working on Keeping You Safe - PoliticalCritique.org - July 20th, 2017 [July 20th, 2017]
- Psychedelic drugs could tackle depression in a way that antidepressants can't - INSIDER - July 22nd, 2017 [July 22nd, 2017]
- Psychedelic Shine takes a trip to the skies in Boulder - Boulder Daily Camera - July 22nd, 2017 [July 22nd, 2017]
- Reasons to Consider Trying Psychedelics - FoxWeekly - July 27th, 2017 [July 27th, 2017]
- Psychedelics and Normality - HuffPost - July 27th, 2017 [July 27th, 2017]
- New book about psychedelics and weird human experiences - Boing Boing - July 27th, 2017 [July 27th, 2017]
- Scientists Want You to Give Them Money to Study ... - July 29th, 2017 [July 29th, 2017]
- What Has Awe Done for Me Lately? - HuffPost - August 1st, 2017 [August 1st, 2017]
- For children, it's beyond psychedelics - The Hans India - The Hans India - August 1st, 2017 [August 1st, 2017]
- Expanding consciousness - 48 Hills - August 2nd, 2017 [August 2nd, 2017]
- THE FUTURE OF PSYCHEDELICS: Are LSD and Mushrooms The New Prozac? - Dope Magazine - August 5th, 2017 [August 5th, 2017]
- Psychedelic drugs saved my life. So why aren't they prescribed? - Wired.co.uk - August 9th, 2017 [August 9th, 2017]
- LSD as therapy: How scientists are reclaiming psychedelics ... - August 9th, 2017 [August 9th, 2017]
- The foundation of Western philosophy is probably rooted in psychedelics - Quartz - August 12th, 2017 [August 12th, 2017]
- Crazy Enough to be Correct - HuffPost - August 15th, 2017 [August 15th, 2017]